<DOC>
	<DOCNO>NCT02460458</DOCNO>
	<brief_summary>A 5 - year International Registries Prospective Study VWD Type 3 , aim assess number , type risk factor bleed efficacy safety VWF concentrate use treat VWD patient .</brief_summary>
	<brief_title>Type 3 Von Willebrand International Registries Inhibitor Prospective Study</brief_title>
	<detailed_description>Von Willebrand Disease ( VWD ) common inherit bleeding disorder , characterize quantitative and/or qualitative deficiency von Willebrand factor ( VWF ) , play major role early phase haemostasis . VWD type 3 ( VWD3 ) due virtually complete deficiency VWF , reason , also describe `` severe VWD '' . VWD3 inherit recessive trait heterozygous relative mild bleed symptom . Even prevalence VWD3 low , high rate find Iran low southern Europe . However , actual prevalence VWD3 still unknown country , due lack retrospective prospective study . Although rare , VWD3 major interest severe clinical presentation , need replacement therapy VWF concentrate risk occurrence anti-VWF inhibitor infusion VWF concentrate , risk factor systematically determine . The major objective study : create international network among European Iranian Centers ( ratio 1:1 ) , prospective enrollment 250 VWD3 patient use common database online , collection detail information previous bleeding exposure VWF concentrate , use bleeding severity score VWD3 calculate common questionnaire , evaluation presence VWF gene defect VWF phenotype risk anti-VWF inhibitor , evaluation anti-VWF antibody titre common method , VWD3 gene analysis , observation frequency sit bleed VWD3 followed-up 2 year , efficacy assessment VWF concentrate use treat VWD3 use objective criterion efficacy . To purpose , cohort 250 patient diagnosis Type 3 von Willebrand Disease enrol use homogenous standardize criterion . The work plan achieve objective project divide three part : - first part deal standardize criterion enrolment collection retrospective clinical laboratory data , confirm centralized laboratory ; - second part involve characterization clinical laboratory parameter , collect retrospective phase , include prevalence anti-VWF inhibitor , advance laboratory test identify VWD3 , mutation analysis VWF gene ; - third part study first time deal prospective clinical observation large cohort VWD3 patient previously well characterized international panel expert .</detailed_description>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Von Willebrand Disease , Type 3</mesh_term>
	<criteria>Male female age , include infant , child , adolescent adult Informed Consent obtain ( parent sign patient &lt; 18 y.o . ) Previous Diagnosis VWD3 ( VWF antigen : undetectable &lt; 5 U/dL ) Detailed information inherited pattern , history bleeding , previous exposure blood product Availability plasma DNA sample â€¢ VWD3 patient may available followup</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Factor VIII</keyword>
	<keyword>Hemorrhage</keyword>
	<keyword>von Willebrand Diseases</keyword>
	<keyword>von Willebrand Factor</keyword>
</DOC>